IL10 and neoplasm: The study in vivo found that the different doses of HRCR recovered the loss of body weight, the shortened colon length, the increased tumour counts, the abnormal changes in spleen and thymus indices, the colonic lesions, the unbalanced inflammatory factors levels like IL-10, IL-6, IL-1β, and TNF-α in serum, and the down-regulated intestinal permeability proteins such as Claudin-1, Occludin, and ZO-1.